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Impact of Nesiritide on Renal Function
in Patients With Acute Decompensated
Heart Failure and Pre-Existing Renal Dysfunction
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Ronald M. Witteles, MD,* David Kao, MD,* Dianne Christopherson, PHD, RN,*
Kelly Matsuda, PHARMD,* Randall H. Vagelos, MD, FACC,* Donald Schreiber, MD,†‡
Michael B. Fowler, MB, FACC*
Stanford and Palo Alto, California
Objectives Our purpose was to evaluate the impact of nesiritide on renal function in patients with acute decompensated
heart failure and baseline renal dysfunction.
Background Although nesiritide is approved for the treatment of acute decompensated heart failure, retrospective analyses
have raised concerns that it may cause worsened renal function. To date, no randomized clinical trials have pro-
spectively evaluated this issue.
Methods Consecutive patients with acute decompensated heart failure and baseline renal dysfunction were enrolled in
this randomized, double-blind, placebo-controlled clinical trial. Subjects were randomized to receive nesiritide
(0.01 g/kg/min with or without a 2-g/kg bolus) or placebo (5% dextrose in water) for 48 h in addition to their
usual care. Predefined primary end points of the trial were a rise in serum creatinine by 20% and change in
serum creatinine.
Results Seventy-five patients were enrolled (39 nesiritide, 36 placebo). The groups had similar baseline age (74.9 vs.
75.5 years, respectively), blood pressure (123/64 vs. 125/64 mm Hg) and serum creatinine (1.82 vs. 1.86
mg/dl). There were no significant differences in the incidence of a 20% creatinine rise (23% vs. 25%) or in the
change in serum creatinine (0.05 vs. 0.05 mg/dl). There were no significant differences in the secondary
end points of change in weight (2.19 vs. 1.58 kg), intravenous furosemide (125 vs. 107 mg), discontinuation
of the infusion due to hypotension (13% vs. 6%), or 30-day death/hospital readmission (33% vs. 25%).
Conclusions In this randomized, double-blind, placebo-controlled clinical trial, nesiritide had no impact on renal function in
patients with acute decompensated heart failure. (BNP-CARDS trial; http://www.clinicaltrials.gov/ct/show/
NCT00186329?order1; NCT00186329) (J Am Coll Cardiol 2007;50:1835–40) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.071f
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lne of the main challenges in the treatment of acute
ecompensated heart failure (ADHF) is worsened renal
unction. Renal dysfunction independently predicts a worse
utcome in heart failure in general and ADHF in particular
1–12). Importantly, it is during the treatment period for
DHF when the effects are most significant, as a decline in
enal function during ADHF therapy is a worse prognostic
rom the *Division of Cardiovascular Medicine, †Department of Emergency Med-
cine, Stanford University School of Medicine, Stanford, California; and the ‡Palo
lto Veterans Administration Hospital, Palo Alto, California. This trial was an
nvestigator-initiated study funded by Scios, Inc. Dr. Fowler has received consulting
ees/honoraria from Scios, and Drs. Fowler and Schreiber have received research
upport from Scios.n
Manuscript received February 12, 2007; revised manuscript received March 26,
007, accepted March 28, 2007.actor than the presence of baseline renal dysfunction
6–8,10–12). Loop diuretics, the mainstay of therapy for
DHF, are associated with worsened renal function, acti-
See page 1841
ation of the renin-angiotensin-aldosterone axis, and po-
entially even increased mortality (12–19). The National
eart, Lung, and Blood Institute, in recognition of the
mportance of worsened renal function in heart failure,
efined “cardiorenal syndrome” as a condition “in which
herapy to relieve congestive symptoms of heart failure is
imited by further decline in renal function” and stressed the
eed for urgent study of this condition (20).
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Renal Effects of Nesiritide in HF November 6, 2007:1835–40Nesiritide (human recombi-
nant B-type natriuretic peptide),
approved by the Food and Drug
Administration in 2001, became
the first new therapy for ADHF
in 14 years. Although its primary
mechanism of action is as a sys-
temic and pulmonary vasodilator,
it has multiple effects on the kid-
neys, including promoting natri-
resis, diuresis, and inhibiting the renin-angiotensin-
ldosterone axis (21–23). Previous studies evaluating non-heart
ailure patients and stable heart failure outpatients have dem-
nstrated mixed results regarding the effect of nesiritide on
lomerular filtration rate (GFR), with some studies suggest-
ng an improvement in GFR (even partially attenuating the
egative effects of loop diuretics) and others showing no
mpact (21,24–30).
Although nesiritide’s effect on renal function was not a
rimary end point in prior trials, a meta-analysis published in
005 found that treatment with nesiritide may be associated
ith worsened renal function (31). This study largely ac-
ounted for a dramatic decrease (up to 64%) in the clinical
se of nesiritide for the treatment of ADHF (32). Despite
his controversy and the importance of renal dysfunction in
eart failure outcomes, no study of 15 patients prospec-
ively evaluating this issue has been published to date, and
o study has prospectively evaluated this issue in the usual
linical setting of attempted diuresis (33).
The purpose of this study was to evaluate the effect of
esiritide administration on renal function in a population
ith ADHF and pre-existing renal dysfunction in a pro-
pective, randomized, double-blind, placebo-controlled
linical trial.
ethods
he BNP-CARDS (B-Type Natriuretic Peptide in Car-
iorenal Decompensation Syndrome) trial was performed
rom March 1, 2004, to August 31, 2006, at Stanford
niversity Hospital and from February 1, 2006, to August
1, 2006, at the Palo Alto Veterans Administration Hos-
ital. All newly admitted inpatients during those periods
ith a primary diagnosis of ADHF were screened for the
rial. Further inclusion criteria included a calculated GFR
using the Cockcroft-Gault formula) between 15 to 60
l/min (changed from 15 to 50 ml/min in December 2004
o be consistent with the published definition of “moderate
enal impairment”), and age 18 years (34,35). Exclusion
riteria included baseline hypotension (systolic blood pres-
ure 90 mm Hg), hemodynamically significant aortic
tenosis, need for intravenous (IV) vasodilator therapy,
dmission to an intensive care unit, history of cardiac
ransplantation, allergy to nesiritide, and prior enrollment in
Abbreviations
and Acronyms
ADHF  acute
decompensated heart
failure
GFR  glomerular filtration
rate
IV  intravenoushe trial. Subjects were enrolled within 12 h of hospital tdmission. The protocol was approved by the human
ubjects committees at both study sites.
After written informed consent was obtained, patients
ere randomized in a 1:1 fashion to receive a fixed-dose
esiritide infusion (2-g/kg IV bolus followed by a contin-
ous infusion at 0.01 g/kg/min for 48 h) or matching
lacebo (5% dextrose in water mimicking the same dosing).
andomization was performed by the research pharmacist
t each site using a random number generator. The bolus
ould be held at the discretion of the treating physician
separate from the study investigators) if there was clinical
oncern for the development of significant hypotension,
sually for baseline systolic blood pressure 90 to 109 mm Hg.
he remainder of the medications administered to the
atient (including diuretics) was at the discretion of the
reating physician. Patients were monitored for adverse
eactions to nesiritide, including hypotension. The infusion
as discontinued at the discretion of the treating physician
f the subject developed symptomatic hypotension. Serum
reatinine was measured daily during the infusion. All
linicians and study personnel were blinded to the subject’s
andomization.
The predefined primary end points of the trial were:
. A significant decline in renal function (defined as a peak
serum creatinine increase of 20% at any time during
the first 7 days of hospitalization compared with the
admission creatinine).
. Change in serum creatinine from the admission value to
discharge and/or day 7 of hospitalization, whichever was
sooner.
econdary end points included net negative diuresis 1
/day while on the infusion; change in weight during the
nfusion; need to discontinue the infusion due to hypoten-
ion; total diuretic use while receiving the infusion; median
ength of stay; death or rehospitalization within 30 days; and
esource utilization—defined by need for dialysis, intensive
are monitoring, pulmonary artery catheterization, and in-
ubation. Results were analyzed by Student t test and
hi-square analysis, as appropriate. The study had 80%
ower at an alpha of 0.05 to detect a 28% relative difference
n the first primary end point assuming a 25% event rate,
nd to detect a creatinine difference of 0.20 mg/dl in the
econd primary end point assuming a standard deviation of
.30 mg/dl. Data were analyzed in an intention-to-treat
ashion.
esults
f 514 consecutive patients admitted with ADHF, 75 met
nclusion/exclusion criteria and provided informed consent.
The baseline characteristics of the 2 groups were similar
Table 1). In particular, average age and serum creatinine
ere very similar between the 2 groups. A large portion of
atients in each group (46% in the nesiritide group, 50% of
he placebo group) were over 79 years of age.
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November 6, 2007:1835–40 Renal Effects of Nesiritide in HFThere was no difference in the primary end points of renal
ysfunction—either a20% increase in serum creatinine, or
he change in creatinine from the admission value (Fig. 1,
able 2). There was no significant difference in net weight
oss or net fluid balance between the 2 groups, with slight
rends for more weight loss/net negative fluid balance in the
esiritide group balanced by a trend toward higher doses of
iuretics administered to that group. There were no gender-
ased differences in the results in either group.
aseline Characteristics
Table 1 Baseline Characteristics
Characteristics
Nesiritide
(n  39)
Placebo
(n  36) p Value
Age, mean (yrs) 74.9 75.5 0.85
% male 67 61 0.62
Admission creatinine (mg/dl) 1.82 1.86 0.79
Admission GFR (ml/min, estimated) 35 33 0.48
% systolic dysfunction (LVEF 45%) 55 62 0.58
Outpatient furosemide dose (mg/day) 65 55 0.50
Systolic blood pressure (mm Hg) 123 125 0.77
Diastolic blood pressure (mm Hg) 64 64 0.87
% of patients taking
Beta-blocker 72 58 0.22
ACE-I and/or ARB 51 47 0.73
Aldosterone antagonist 15 11 0.59
Digoxin 28 25 0.75
Amiodarone 21 6 0.06
Calcium blocker 23 25 0.85
Long-acting nitrate 23 28 0.64
Hydralazine 5 25 0.02
History of (%)
Heart failure 90 89 0.90
Coronary artery disease 77 56 0.0499
COPD 26 19 0.52
Diabetes mellitus 56 44 0.30
Atrial fibrillation 44 36 0.51
Cerebrovascular accident 8 19 0.13
alues in bold indicate statistical significance.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; COPD 
hronic obstructive pulmonary disease; GFR  glomerular filtration rate; LVEF  left ventricular
jection fraction.
Figure 1 Incidence of Worsened Renal Function
Incidence of 20% rise in creatinine (Cr) by discharge or day 7 of the hospital-
ization. No significant difference was observed in the primary end point of wors-
ened renal function (increase in serum creatinine 20%) (p  0.85).There were no statistically significant differences in com-
lications/adverse outcomes between the 2 groups, although
here was a nonsignificant trend for the infusion being
topped more frequently in the nesiritide group due to
ypotension (Table 3). Systolic and diastolic blood pressures
rended lower in the nesiritide group at almost all time
oints, with significantly lower values than in the placebo
roup at 3, 6, and 12 h (Fig. 2).
Thirty-five percent of subjects had their bolus held by the
reating physician (33% randomized to nesiritide, 36%
andomized to placebo, p  NS). Subjects who received a
olus had higher baseline systolic blood pressures than
ubjects who had the bolus withheld (132 vs. 110 mm Hg,
 0.0001). Subjects who received a nesiritide bolus had a
onsignificant trend (p  0.15) toward a larger drop in
ystolic blood pressure 1 h after the infusion started (8.6
m Hg) than those who had the bolus held (0.9 mm Hg).
here was no significant association between receiving a
olus and any of the predefined end points.
iscussion
he main finding of this study was that, in a cohort of
atients with baseline renal insufficiency and ADHF, ad-
inistration of nesiritide in addition to standard therapy did
ot result in worsened renal function. Importantly, admin-
stration of nesiritide did not protect against the develop-
ent of renal dysfunction either. Therefore, whereas ne-
iritide appears to be safe in this population of patients from
renal standpoint, this trial provided no evidence for a
herapeutic role to protect renal function.
One possible explanation for the disparate findings be-
ween this and previous studies is the use of a bolus dose. In
utcomes
Table 2 Outcomes
Outcome
Nesiritide
(n  39)
Placebo
(n  36) p Value
Change in creatinine (mg/dl) 0.05 0.05 0.46
Diuresis 1 l/24 h (%) 49 48 0.91
Length of stay (median days) 4 4
Length of stay (mean days) 5.85 5.67 0.91
Weight loss (kg) 2.19 1.58 0.26
Net fluid balance (l) 1.99 1.90 0.86
IV furosemide during infusion (mg) 124.5 106.7 0.53
Oral furosemide during infusion (mg) 34.8 28.8 0.45
V  intravenous.
dverse Events
Table 3 Adverse Events
Event
Nesiritide (%)
(n  39)
Placebo (%)
(n  36) p Value
Infusion stopped for hypotension 5 (13) 2 (6) 0.28
Transfer to intensive care unit 4 (10) 3 (8) 0.77
Dialysis 0 (0) 1 (3) 0.29
Mechanical ventilation 0 (0) 1 (3) 0.29
30-day mortality 4 (10) 2 (6) 0.4530-day mortality/readmission 13 (33) 9 (25) 0.43
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Renal Effects of Nesiritide in HF November 6, 2007:1835–40ost previous studies, a 2-g/kg IV bolus dose was admin-
stered to patients, as per the protocol in the VMAC
Vasodilation in the Management of Acute Congestive
eart Failure) trial (36). The majority of the VMAC trial
opulation consisted of patients who, in the clinicians’
udgment, required a pulmonary artery catheter for manage-
ent before being enrolled in the trial (36). Their clinical
haracteristics—an average pulmonary capillary wedge pres-
ure of 28 mm Hg, an average systemic vascular resistance of
ver 1,400 dynes/s/cm5, and the clinical need for a pulmo-
ary artery catheter—were such that a large bolus of a
asodilator might be desirable. This represents a very
ifferent population from many ADHF patients, who rarely
equire a pulmonary artery catheter and who can usually
fford the 1 to 2 h necessary to gradually reach steady-state
oncentration of the drug. Indeed, for a drug with a half-life
f approximately 20 min, steady-state concentrations are
eached relatively quickly with the continuous IV infusion
ithout administering a bolus. It is certainly conceivable
hat any positive or neutral effects of nesiritide on GFR
ight be overcome by significant hypotension occurring
ith the bolus dose, possibly accounting for some of the
orsened renal function seen in other retrospective analyses.
he recently published NAPA (Nesiritide Administered
eri-Anesthesia in Patients Undergoing Cardiac Surgery)
rial found that perioperative use of nesiritide in patients
ith left ventricular dysfunction undergoing coronary artery
ypass grafting protected against renal dysfunction and was
otable for the fact that a bolus dose was not included in the
rotocol (37). The patients in the NAPA trial were very
ifferent from those evaluated in our trial, most notably
ecause the NAPA trial cohort did not evaluate patients
ith ADHF (for whom nesiritide is Food and Drug
dministration approved). Although only 1 of the 5 sub-
ects in our study who had the nesiritide infusion discon-
Figure 2 Blood Pressure Change During Infusion
Blood pressure change is recorded in reference to the start of the infusion
(time  0). Time “off” refers to 3 h after the infusion was stopped
(solid lines  systolic blood pressure change; dashed lines  diastolic blood
pressure change; green  placebo; red  nesiritide). p  0.05 versus placebo
at 6 and 12 h for systolic blood pressure, and at 3 h for diastolic blood
pressure.inued due to hypotension received a bolus, this is likely a peflection of the fact that the group who received the bolus
ad significantly higher baseline blood pressure than the
roup who had the bolus withheld. Receiving a nesiritide
olus was associated with a trend toward developing a larger
rop in systolic blood pressure at 1 h in our study.
A second difference between our trial and other studies is
he dose of nesiritide infusion used. In our trial, all patients
andomized to the nesiritide arm received the recommended
tarting dose of 0.01 g/kg/min, a dose that retrospective
nalyses have found to be more consistent with a neutral or
ositive effect on renal function (38,39). Past studies have
sed doses between 0.01 and 0.06 g/kg/min, with higher
oses leading to more hypotension and more reports of
orsened renal function (31,36,39).
Another possible difference between the results of our
rial and observations from previous trials is the timing
hen the nesiritide infusion was initiated. In our study, all
atients were started within 12 h of hospitalization, before
hey might have otherwise been aggressively diuresed with
oop diuretics. This earlier administration may have con-
ributed to a lower incidence of hypotension, and may have
lso prevented up-regulation of the renin-angiotensin-
ldosterone system otherwise associated with loop diuretic
dministration (14–16,19,20).
A final important difference between our study and earlier
rials is the makeup of the study population. Our trial
esign, which targeted all consecutive patients who met
ntry criteria, was intended to yield a patient population
epresentative of admissions for heart failure in the general
opulation—and not surprisingly included many patients of
dvanced age (48% of patients were 79 years of age) and
any patients with heart failure with preserved systolic
unction (42%). This is opposed to a mean age of 61 years
nd only 15% of patients with a left ventricular ejection
raction 40% in the VMAC trial (36). Importantly, older
verage age and higher prevalence of preserved systolic
unction are both characteristics of the “cardiorenal” patient
3,6,7,11).
Patients in the nesiritide group did develop significantly
ower systolic and diastolic blood pressure, with a trend
oward the infusion needing to be discontinued for hypo-
ension more frequently. Despite this lower blood pressure,
atients in the nesiritide group did not develop worsened
enal dysfunction. A possible explanation may be the bal-
nce of “direct” and “indirect” effects of natriuretic peptides
n renal function. Direct effects of natriuretic peptides serve
o increase GFR by relaxing renal mesangial cells, dilating
he afferent renal arteriole, and constricting the efferent
enal arteriole; indirect effects serve to decrease GFR by
nhibiting the renin-angiotensin-aldosterone and sympa-
hetic axes and by lowering systemic blood pressures and
irculating blood volume (21,40–43). It is likely the balance
f these direct and indirect effects that causes GFR to
ncrease, decrease, or stay the same in individual patients. In
ur cohort of patients with nesiritide administered per our
rotocol, the net effect on GFR was neutral.
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November 6, 2007:1835–40 Renal Effects of Nesiritide in HFThere were several important limitations to this study.
lthough this represents the largest randomized trial to
rospectively evaluate the effect of nesiritide on renal func-
ion in ADHF, the number of participants still could allow
or a type II error. A large treatment effect on the primary
nd points is unlikely given the lack of even a trend in either
irection, but a smaller and potentially clinically relevant
ffect is still possible. Another limitation to this trial was the
xclusion of important subgroups of ADHF patients, in-
luding those needing intensive care and those requiring IV
asodilator therapy; the results of this trial certainly do not
xclude a potentially important effect of nesiritide (positive
r negative) on renal function in those patients. Finally,
lthough our trial was not powered to evaluate mortality and
ospital readmission, there were nonsignificant trends ob-
erved in favor of placebo. Due to the relatively small sample
ize, the lack of statistical significance does not rule out
ifferences in these outcomes.
onclusions
he results of this prospective, randomized, double-blind,
lacebo-controlled clinical trial indicate that nesiritide ther-
py does not cause or prevent worsened renal function in
atients with ADHF and pre-existing renal dysfunction.
ata regarding the renal effects of nesiritide therapy in other
atient populations, and effects on other clinical end points,
wait the result of other randomized trials.
eprint requests and correspondence: Dr. Ronald M. Witteles,
ivision of Cardiovascular Medicine, Stanford University School
f Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, California
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